Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 229-904-5 | CAS number: 6829-22-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 016
- Report date:
- 2016
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Principles of method if other than guideline:
- The toxicity of the test item Macrolex Rot E2G (CAS-No. 6829-22-7) following daily oral (gavage) administration for 4 weeks in the rat was determined.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 14H-benz[4,5]isoquino[2,1-a]perimidin-14-one
- EC Number:
- 229-904-5
- EC Name:
- 14H-benz[4,5]isoquino[2,1-a]perimidin-14-one
- Cas Number:
- 6829-22-7
- Molecular formula:
- C22H12N2O
- IUPAC Name:
- 14H-benz[4,5]isoquino[2,1-a]perimidin-14-one
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- Purity/Content: 99.9 %.
Appearance: Dark red powder.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Wistar rats: Crl: WI (Han)
- Details on species / strain selection:
- One of the rodent species acceptable to the regulatory agencies. Historical control data for the strain are available at the Test Facility.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Test system
Species/strain: Wistar rats: Crl: WI (Han)
Supplier: Charles River Laboratories France, Domaine des Oncins, 69210 Saint-Germain-Nuelles, France
Number of animals in the study: 40 (20 males and 20 females). Four spare animals (2 males and 2 females) were purchased. As not used in this study, they were returned to stock
Age at initiation of treatment: Approximately 6 weeks.
Body weight range at initiation of - males: 148 to 176 g
treatment: - females: 137 to 153 g
Animal husbandry
Housing: One air-conditioned room in a barrier protected unit
Temperature: 22 + 3 °C (target range)
Relative humidity: 35 to 70 % (target range)
Air changes: At least 10 air changes per hour
Lighting cycle: 12 hours light (artificial)/12 hours dark (except when required for technical acts)
Caging: Animals were housed in groups of 5 of the same sex and dose group in plastic cages with sawdust bedding, in compliance with European Regulations (Directive 2010/63/EU).
Bedding: Dust-free sawdust (SDS/Dietex, Argenteuil, France) made from spruce tree wood, analysed at least twice a year for chemical and bacterial contaminants. A small amount (handful) of shredded paper was provided as enrichment.
Diet: Rat pelleted complete diet ad libitum (Diet reference A04C-10) sterilised by irradiation and analysed for a predefined list of chemical and bacteriological contaminants. Each batch of diet is supplied with a certificate of analysis which is verified and authorized for release by a veterinarian.
The animals were fasted for approximately 16 hours before clinical laboratory blood sampling, during urine collection and before necropsy.
Water: Softened and filtered (0.2 μm) mains drinking water was available ad libitum (via an automatic watering system). Water is analysed twice a year for chemical and bacterial contaminants.
Animals were deprived of water during urine collection
Contaminants: No known contaminants were present in the bedding, drinking water or diet at levels which might have interfered with achieving the objectives of the study
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 1 % (w/v) Carboxymethylcellulose, 400-800 centipoises.
- Details on oral exposure:
- Vehicle
Denomination: 1 % (w/v) Carboxymethylcellulose 400-800 centipoises.
Supplier: Sigma.
Storage: At room temperature (between +15 and +25 °C)
Water for injection: Supplier: Aguettant.
Storage: At room temperature (between +15 and +25 °C)
Frequency of preparation: Weekly.
Storage: At room temperature (between +15 and +25 °C)
Test item preparation
Preparation: The test item was prepared as a suspension in the vehicle at concentrations of 10, 30 and 100 mg/mL
Correction factor for active
ingredient: None.
Homogenecity of test item in
vehicle: Suspensions at concentrations of 1.00 to 100 mg/mL have been shown to be homogeneous
Stability of the test item in the
vehicle: Suspensions at concentrations of 1.00 to 100 mg/mL have been demonstrated to be stable for 24 hours and 8 days at room temperature (between +15 and +25 °C) protected from light or refrigerated
(between +2 and +8 °C)
Frequency of preparation: Weekly.
Storage of formulations: At room temperature (between +15 and +25 °C). - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analysis of preparations:
Four samples of 1 g were taken from each formulation including the control, used on the first day of treatment and on a suitable day during the last week of treatment. The samples were stored at room temperature (between +15 and +25 °C) until analysis.
One set of samples was analysed at the Test Facility within the stability period using a validated method. - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 100, 300, 1000 mg/kg bw/day
Basis:
actual ingested
- No. of animals per sex per dose:
- 5 males + 5 females/dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Rationale for the dose selection: in preliminary study AB20659 conducted in the rat, the test item administered at the dose level of 500 and 1000 mg/kg bw/day for 5 days was well tolerated.
Examinations
- Observations and examinations performed and frequency:
- Morbidity/mortality, clinical signs, body weight, food consumpton, modified Irwin test (neurological function assessment), haematology, serum clinical chemistry, urine analysis
- Sacrifice and pathology:
- Pathology
On the day after the last dose (i.e. day 28), the animals were necropsied randomized. The animals were fasted overnight before necropsy.
The animals were killed by carbon dioxide inhalation and weighed and then exsanguinated.
All animals were submitted to full necropsy procedures including examination of the following:
external surface
all orifices
cranial cavity
the carcass
external surface of the brain and cervical spinal cord
thoracic and abdominal cavities and organs
cervical tissues and organs
Organ weights
The organs listed in the organ processing table were weighed at necropsy for all animals. Paired organs were weighed together.
Organs were weighed after dissection of fat and other contiguous tissues.
Organ weights were expressed as absolute values (g) and relative values (g per 100 g of body weight).
Histopathology
The following organs/tissues for all animals in groups 1 (control) and 4 (high dose) killed at the end of the treatment period, were examined histologically:
Adrenal glands, Aorta, Bone (femur) and articulation , Bone (sternum) with bone marrow, Bone marrow smears, Brain, Bronchi (mainstem) , Caecum , Cervix, Colon, Duodenum , Epididymides, Eyes, Harderian glands, Heart, Ileum with Peyer‘s patches, Jejunum, Kidneys, Liver, Lungs, Lymph nodes (mandibular), Lymph node (mesenteric), Mammary gland , Nasal cavity and Zymbal’s glands, Oesophagus, Optic nerves, Ovaries, Oviducts, Pancreas, Parathyroid glands, Pituitary gland, Prostate, Rectum, Salivary glands (mandibular, parotid, sublingual), Sciatic nerve (left), Seminal vesicles including coagulation gland, Skeletal muscle, Skin, Spinal cord (cervical, thoracic, lumbar), Spleen, Stomach, Testes, Thymus, Thyroid glands, Tongue, Trachea, Urinary bladder, Uterus, Vagina. - Statistics:
- The following parameters were analysed statistically on each occasion for males and females separately:
− body weights and body weight gains
− haematology, coagulation and serum clinical chemistry parameters, urine volume, specific gravity and urine pH
− terminal body weights, absolute and relative organ weights.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No test item-related clinical signs were noted.
- Mortality:
- no mortality observed
- Description (incidence):
- No mortality occurred during the study.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Body weight was not affected by the administration of the test item.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Food consumption was not affected by the administration of the test item.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- No test item-related effects were noted in haematological parameters.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- No test item-related effects were noted in blood biochemistry parameters.
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- No test item-related effects were noted in urinary parameters.
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- After 4 weeks of treatment, when compared with the vehicle control group, no relevant effect was noted on the behaviour and physiological parameters of the animals observed 1 hour after dosing with Macrolex Rot E2G at 100, 300 or 1000 mg/kg bw/day.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- There were no test item-related alterations in organ weights.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- There were no gross observations that were considered to be test item-related.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- There were no histological observations that were considered to be test item-related.
- Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- There were no histological observations that were considered to be test item-related.
- Other effects:
- no effects observed
- Description (incidence and severity):
- There were no test item-related pathological changes.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No test item-related in vivo effects and no test item-related histopathological changes were observed at the highest applied dose (1000 mg/kg bw/day).
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Any other information on results incl. tables
No test item-related in vivo effects and no test item-related histopathological changes were observed.
The daily oral administration of Macrolex Rot E2G for 28 days to Wistar rats at the dose levels of 100, 300 or 1000 mg/kg bw/day did not induce any effects during the in vivo phase. No test item related histopathological changes were noted.
Based on the results of this study, the dose level of 1000 mg/kg bw/day was considered as a No Observed Adverse Effect Level (NOAEL).
Applicant's summary and conclusion
- Conclusions:
- The daily oral administration of Macrolex Rot E2G for 28 days to Wistar rats at the dose levels of 100, 300 or 1000 mg/kg bw/day did not induce any effects during the in vivo phase. No test item related histopathological changes were noted.
- Executive summary:
The test item Macrolex Rot E2G (CAS-Nr. 6829-22-7) was applied daily per gavage for 4 consecutive weeks in doses of 0 (control), 100, 300 or 1000 mg/kg bw to male and female rats.
Morbidity/mortality checks were performed at least twice daily. Clinical observations were performed daily. A full clinical examination was performed weekly. Individual body weights were recorded weekly. Food consumption was measured weekly for each cage of animals. Modified Irwin test (Neurological Function Assessment) was performed pretest and in week 4. Clinical laboratory determinations were performed in week 4.
All animals were killed at the end of the treatment period and necropsied. Selected organs were weighed. Organ/tissue samples were fixed and preserved at necropsy for all animals. Selected organs/tissues from group 1 (0 mg/kg bw/day) and 4 (1000 mg/kg bw/day) animals killed at the end of the treatment period were examined histopathologically.
No test item-related in vivo effects and no test item-related histopathological changes were observed.
The daily oral administration of Macrolex Rot E2G for 28 days to Wistar rats at the dose levels of 100, 300 or 1000 mg/kg bw/day did not induce any effects during the in vivo phase. No test item related histopathological changes were noted.
Based on the results of this study, the dose level of 1000 mg/kg bw/day was considered as a No Observed Adverse Effect Level (NOAEL).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.